1-20 of 42
John Hilton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT188: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer

Free
William McKean, Philippe L. Bedard, Phuong Dinh, Dhabusha Sabanathan, Toon Van Gorp, John Hilton, Katriina Jalkanen, Isabelle Ray-Coquard, Domenica Lorusso, Shigehisa Kitano, Marloes GJ Van Rijn-Van Drongen, Valentina Boni, Victor Moreno, Lisa Liu Burström, Alexander Philipovskiy, Alina Goetz, Julie Holden, Shruti Shah, Jeremy Waight, Francisco J. Gonzalez Carreras, Antonio Riccio, Morrys C. Kaisermann, Jennifer Veneris, Minal Barve
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT188.
https://doi.org/10.1158/1538-7445.AM2025-CT188
Published: 25 April 2025
View articletitled, Abstract CT188: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer
Journal Articles

Abstract CT148: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab plus chemotherapy in patients with advanced solid tumors

Free
Rafal Dziadziuszko, Sofia Baka, Eytan Ben Ami, Maria Jose de Miguel Luken, Marta Gil-Martin, John Hilton, Iwona Lugowska, Ruth Perets, Leah Suttner, Douglas C. Wilson, Omobolaji O. Akala, Penelope Bradbury
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT148.
https://doi.org/10.1158/1538-7445.AM2025-CT148
Published: 25 April 2025
View articletitled, Abstract CT148: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab plus chemotherapy in patients with advanced solid tumors
Journal Articles

Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors

Free
Hye Ryun Kim, Philippe Cassier, Gennaro Daniele, Giuseppe Curigliano, John Hilton, Antoine Italiano, Shigehiro Koganemaru, Ruben Kowalyszyn, Patricia LoRusso, Victor Moreno, Maria Eugenia Olmedo Garcia, Herman Perroud, Wasif Saif, Noboru Yamamoto, Amine Aziez, Rana Anjum, John LaMacchia, Ravi Kasinathan, Stefan Symeonides, Jireh Huang, Vivek Subbiah
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT195.
https://doi.org/10.1158/1538-7445.AM2025-CT195
Published: 25 April 2025
View articletitled, Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors
Journal Articles

Abstract CT239: IND.241: A Canadian cancer trials group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer

Free
Moira Rushton, Dave W. Cescon, Nathalie Levasseur, Michelle B. Nadler, Daniel Rayson, Brooke E. Wilson, Sara K. Taylor, Rossanna Pezo, Arif Awan, Zahi Mitri, Vikaash Kumar, Jennifer Melvin, John Hilton, Stephen Chia, Philippe L. Bedard, Spencer Finn, Wei Tu, Courtney Coschi, Philippe Jamme, Elia Aguado-Fraile, Lesley Katie Seymour, Laura Pearce
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT239.
https://doi.org/10.1158/1538-7445.AM2025-CT239
Published: 25 April 2025
View articletitled, Abstract CT239: IND.241: A Canadian cancer trials group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer
Journal Articles

Abstract PO2-20-04: TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer

Free
Claudine Isaacs, Katarzyna Jerzak, John Hilton, José Luiz Miranda Guimarães, Rachel Layman, Dongrui Lu, Gary Mo, Anna Maria Calella, Olga Valota, Sibyl Anderson, Cynthia Ma
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-20-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-20-04
Published: 02 May 2024
View articletitled, Abstract PO2-20-04: TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer
Journal Articles

Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes

Free
Igor Machado, Lucas Clemons, Carol Stober, Gregory Pond, Arif Awan, Henry Conter, Demetrios Simos, Sukhbinder Dhesy-Thind, Mihaela Mates, Vikaash Kumar, John Hilton, Lisa Vandermeer, Mark Clemons
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-13-01.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-13-01
Published: 02 May 2024
View articletitled, Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes
Journal Articles

Abstract PO2-12-12: REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancer

Free
Terry Ng, Yuxin Zhang, Carol Stober, Jennifer Shamess, Natalie Mills, Stuart Nicholls, Mohammed Ibrahim, Daniel Davoudpour, Christopher Armiento, Marie-France Savard, Moira Rushton, Arif Awan, Sandeep Sehdev, John Hilton, Xinni Song, Rakesh Goel, Fiona Macdonald, Kelly Daigle, Lisa Vandermeer, Monica Taljaard, Mark Clemons
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-12-12.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-12-12
Published: 02 May 2024
View articletitled, Abstract PO2-12-12: REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancer
Journal Articles

Abstract PO2-17-01: Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study

Free
Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, Jan-Willem Henning, Swati Kulkarni, Nadia Califaretti, John Hilton, Cristiano Ferrario, Nathaniel Bouganim, Mihaela Mates, Stephanie Guillemette, Ricardo Leite, Stephen Chia
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-17-01.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-17-01
Published: 02 May 2024
View articletitled, Abstract PO2-17-01: Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study
Journal Articles

Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC)

Free
Byoung Chul Cho, John Hilton, Cristina P. Rodriguez, Marcelo Bonomi, Lillian L. Siu, Marta Gil-Martin, Shabana Siddiqi, Nicole M. Myer, Leah Suttner, Douglas Wilson, Omobolaji Akala, Rafal Dziadziuszko
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT114.
https://doi.org/10.1158/1538-7445.AM2024-CT114
Published: 05 April 2024
View articletitled, Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC)
Journal Articles

Abstract CT104: Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors

Free
Lillian L. Siu, Marta Gil-Martin, Byoung Chul Cho, Ruth Perets, John Hilton, Ravit Geva, Iwona Lugowska, Martin Gutierrez, Marcelo Bonomi, Rafal Dziadziuszko, Drew Rasco, Eytan Ben-Ami, Cristina P. Rodriguez, Shabana Siddiqi, Nicole Myer, Leah Suttner, Douglas Wilson, Omobolaji O. Akala, Maria de Miguel
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT104.
https://doi.org/10.1158/1538-7445.AM2024-CT104
Published: 05 April 2024
View articletitled, Abstract CT104: Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors
Journal Articles

Abstract P5-04-04: Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?

Free
Ana-Alicia Beltran-Bless, Bader I. Alshamsan, Mashari Alzahrani, John Hilton, Kelly-Anne Baines, Vicky Samuel, Gregory R. Pond, Lisa Vandermeer, Mark Clemons, Gail Larocque
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-04-04.
https://doi.org/10.1158/1538-7445.SABCS22-P5-04-04
Published: 01 March 2023
View articletitled, Abstract P5-04-04: Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?
Journal Articles

Abstract P6-10-13: An update to a Phase I trial of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors with HER2-negative breast cancer expansion cohorts

Free
John Hilton, Daniel Renouf, David W. Cescon, Aaron Hansen, Alibiruni Abdul Razak, Lee-Anne Stayner, Trisha A. Denny, Emily Roberts-Thomson, Dih-Yih Chen, Mark Bray, Philippe Bedard
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-10-13.
https://doi.org/10.1158/1538-7445.SABCS22-P6-10-13
Published: 01 March 2023
View articletitled, Abstract P6-10-13: An update to a Phase I trial of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors with HER2-negative breast cancer expansion cohorts
Journal Articles

Abstract P3-07-10: CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC)

Free
Philippe Bedard, Mihaela Mates, John Hilton, Nathalie Levasseur, Arif Awan, Amirrtha Srikanthan, David W. Cescon, Karen Gelmon, Andrew Robinson, Nancy Drummond-Ivars, Irene Li, Laleh Rastgou, Jackie Edwards, Linda Hagerman, Siwei Zhang, Mark Bray, Lesley Seymour, Moira Rushton, Pierre-Olivier Gaudreau
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-10.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-10
Published: 01 March 2023
View articletitled, Abstract P3-07-10: CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC)
Journal Articles

Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)

Free
John Hilton, David W. Cescon, Andrew Robinson, Sukhbinder Dhesy-Thind, Sara Taylor, Arif Awan, Terry L. Ng, Moira Rushton, Marie-France Savard, Lindsay Muyot, Marie Claude Reeves, Linda Hagerman, Hongbo Lui, Mark Bray, Dongsheng Tu, Lesley Seymour, Pierre-Olivier Gaudreau
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-18.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-18
Published: 01 March 2023
View articletitled, Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)
Journal Articles

Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237

Free
David W. Cescon, John Hilton, Philippe Bedard, Phillip Blanchette, Rossanna C. Pezo, Ayesha Bashir, Vikaash Kumar, Terry L. Ng, Arif Awan, Anthony Lott, Jacques Antoun Raphael, Linda Hagerman, Mark Bray, Lindsay Muyot, Jesus Fuentes Antras, Lesley Seymour, Dongsheng Tu, Pierre-Olivier Gaudreau, Moira Rushton
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-14.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-14
Published: 01 March 2023
View articletitled, Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237
Journal Articles

Abstract P2-02-04: De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12

Free
Ana-Alicia Beltran-Bless, Mark Clemons, Christian Fesl, Dominik Hlauschek, Lidija Soelkner, Gregory R. Pond, Lisa Vandermeer, Richard Greil, Marija Balic, Vesna Bjelic-Radisic, Christian F. Singer, Guenther Steger, Ruth Helfgott, Daniel Egle, Simon P. Gampenrieder, Stephanie Kacerovsky-Strobl, Christoph Suppan, Magdalena Ritter, Gabriel Rinnerthaler, Georg Pfeiler, Hannes Fohler, John Hilton, Michael Gnant
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-02-04.
https://doi.org/10.1158/1538-7445.SABCS22-P2-02-04
Published: 01 March 2023
View articletitled, Abstract P2-02-04: De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Journal Articles

Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)

Free
Sharon F Mc Gee, Mark Clemons, Michelle Liu, Mashari Jemaan Alzahrani, Terry Ng, Arif Awan, Sandeep Sehdev, John Hilton, Jean Michel Caudrelier, Marie France Savard, Lesley Fallowfield, Vikaash Kumar, Orit Freedman, Dean Fergusson, Gregory Pond, Brian Hutton, Jean Marc Bourque
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-01-01.
https://doi.org/10.1158/1538-7445.SABCS21-OT1-01-01
Published: 15 February 2022
View articletitled, Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)
Journal Articles

Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts

Free
John Hilton, Daniel J Renouf, David W Cescon, Aaron R Hansen, Albiruni RA Razak, Lee-Anne Stayner, Trisha Denny, Graham Fletcher, Tak W Mak, Mark Bray, Philippe L Bedard
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-17.
https://doi.org/10.1158/1538-7445.SABCS21-P1-18-17
Published: 15 February 2022
View articletitled, Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts
Journal Articles

Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

Free
Xi (Cindy) Chen, Lora Hamuro, Shodeinde Coker, John Hilton, Jennifer R. Diamond, Capucine Baldini, Mark Voskoboynik, Mihaela Cristea, William Edenfield, Kezi Unsal-Kacmaz, Donald Jackson, Abraham Apfel, Ke Xu, Li Zhu, Amit Roy, Akintunde Bello, Ronald Fleming, Paul Statkevich
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3021.
https://doi.org/10.1158/1538-7445.AM2020-3021
Published: 15 August 2020
View articletitled, Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158
Journal Articles

Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies

Free
John Hilton, Karen Gelmon, David Cescon, Anna Tinker, Derek Jonker, Rachel Goodwin, Scott Laurie, Aaron Hansen, Samuel Aparicio, John Soong, Linda Hagerman, Hongbo Lui, Philippe Bedard, Kathleen Pritchard, Dongsheng Tu, Lesley Seymour
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD4-02.
https://doi.org/10.1158/1538-7445.SABCS19-PD4-02
Published: 15 February 2020
View articletitled, Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies